ALNY — Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Q4 and Full Year 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Net Product Revenues: Nearly $3 billion for 2025, representing an 81% increase from 2024.
• Q4 Revenues: $995 million, up 121% year-over-year and 17% quarter-over-quarter.
• TTR Franchise Performance: Global TTR revenues reached $858 million in Q4, an 18% increase from Q3 and 151% year-over-year growth.
• GAAP Profitability: Achieved for the full year 2025, with non-GAAP operating income of $850 million.
• Cash Position: Ended 2025 with $2.9 billion in cash and equivalents, up from $2.7 billion in 2024.

2. Strategic Updates and Business Highlights

• Product Launches: Successful launch of Amvuttra for ATTR cardiomyopathy, contributing significantly to revenue growth.
• Pipeline Expansion: Over 25 clinical programs in development, with three Phase 3 studies initiated in 2025.
• New Manufacturing Platform: Launched Cyrillis, an enzymatic ligation-based RNAi manufacturing platform aimed at expanding capacity and reducing costs.
• Long-Term Goals: Introduced "Alnylam 2030" goals focusing on TTR leadership, sustainable innovation, and disciplined growth, targeting a 25% revenue CAGR through 2030.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Combined net product sales expected to be between $4.9 billion and $5.3 billion, representing a 71% increase at the midpoint compared to 2025.
• TTR Revenue Guidance: Projected between $4.4 billion and $4.7 billion for 2026, reflecting an 83% increase at the midpoint.
• R&D and SG&A Expenses: Combined expenses anticipated to be between $2.7 billion and $2.8 billion, a 26% increase from 2025.

4. Bad News, Challenges, or Points of Concern

• Pricing Dynamics: Anticipated mid-single-digit net price decrease for Amvuttra in 2026, which may impact revenue growth.
• International Market Challenges: Expected modest revenue growth in international markets due to pricing adjustments for the cardiomyopathy indication.
• Q1 2026 Revenue Phasing: Lower anticipated growth in Q1 compared to Q4 2025 due to fewer shipping weeks and annual insurance reauthorizations.

5. Notable Q&A Insights

• Market Dynamics: Management expressed confidence in Amvuttra's market share growth, particularly in first-line treatment settings, despite competitive pressures.
• Competitive Landscape: Acknowledgment of potential competition from emerging therapies, but management believes Alnylam's established position and product profile will sustain its market leadership.
• Pipeline Development: Emphasis on the importance of de-risking programs, with a focus on achieving significant clinical milestones in the coming years, particularly for Huntington’s disease and obesity treatments.
• External Innovation: Discussion on potential partnerships to complement internal pipeline efforts, with a focus on high-science and financially sound opportunities.

Overall, Alnylam Pharmaceuticals demonstrated strong financial performance in 2025, with significant growth driven by the successful launch of Amvuttra and a robust pipeline. However, challenges related to pricing dynamics and international market adjustments were noted, alongside a cautious outlook for Q1 2026.